Cellectar Biosciences Announces European Medicines Agency (Ema) Confirms Eligibility to File for Conditional Marketing Authorization (Cma) for Iopofosine I 131 as a Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm)

THOMSON REUTERS
Oct 06, 2025

Cellectar Biosciences Announces European Medicines Agency (Ema) Confirms Eligibility to File for Conditional Marketing Authorization (Cma) for Iopofosine I 131 as a Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10